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Vitamin D and uterine ﬁbroid growth,
incidence, and loss: a prospective
ultrasound study
Quaker E. Harmon, M.D., Ph.D.,a Stacy A. Patchel, M.P.H,b Sheri Denslow, Ph.D.,c Frankie LaPorte, M.S.,c
Tracy Cooper, R.D.M.S.,d Lauren A. Wise, Sc.D.,e Ganesa Wegienka, Ph.D.,f and Donna D. Baird, Ph.D.a
a
Epidemiology Branch, National Institute of Environmental Health Sciences, Durham, North Carolina; b Public Health
and Epidemiology Practice at Westat, Durham, North Carolina; c Social & Scientiﬁc Systems, Inc., a DLH Holdings
company, Durham, North Carolina; d Division of Ultrasound, Department of Diagnostic Radiology, Henry Ford Health,
Detroit, Michigan; e Department of Epidemiology, Boston University School of Public Health, Boston, Massachusetts;
and f Department of Public Health Sciences, Henry Ford Health, Detroit, Michigan

Objective: Fibroid treatments that have few side-effects and can preserve fertility are a clinical priority. We studied the association
between serum vitamin D and uterine ﬁbroid growth, incidence, and loss.
Design: A prospective community cohort study (enrollment 2010–2012) with 4 study visits over 5 years to conduct standardized ultrasounds, measure 25-hydroxyvitamin D (25(OH)D), and update covariates.
Setting: Detroit, Michigan area.
Patients: Self-identiﬁed African American or Black women aged 23–35 at enrollment without previous clinical diagnosis of ﬁbroids.
Intervention(s): Serum 25(OH)D measured using immunoassay or liquid chromatography-tandem mass spectrometry.
Main Outcome Measure(s): The primary outcomes were ﬁbroid growth, as measured by change in log volume per 18 months, and ﬁbroid
incidence (ﬁrst detection of ﬁbroid in previously ﬁbroid-free uterus). Adjusted growth estimates from linear mixed models were converted to
estimated difference in volume for high vs. low 25(OH)D. Incidence differences were estimated as hazard ratios from age-speciﬁc Cox
regression. A secondary outcome ﬁbroid loss (reduction in ﬁbroid number between visits), was modeled using Poisson regression. Covariates
(reproductive and hormonal variables, demographics, body mass index, current smoking) and 25(OH)D were modeled as time-varying factors.
Result(s): At enrollment among 1,610 participants with R1 follow-up ultrasound, mean age was 29.2 years, 73% had deﬁcient
vitamin D (<20ng/mL), and only 7% had sufﬁcient vitamin D (R30ng/mL). Serum 25(OH)D R20ng/mL compared with <20ng/mL
was associated with an estimated 9.7% reduction in ﬁbroid growth (95% conﬁdence interval [CI]: -17.3%, -1.3%), similar to the
minimally adjusted estimate -8.4% (95% CI: -16.4, 0.3). Serum 25(OH)D R30ng/mL compared with <30ng/mL was associated with
an imprecise 22% reduction in incidence (adjusted hazard ratio¼0.78; 95% CI: 0.47, 1.30), similar to the unadjusted estimate of
0.84 (95% CI: 0.51, 1.39). The >30ng/mL group also had a 32% increase in ﬁbroid loss (adjusted risk ratio¼1.32; 95% CI: 0.95, 1.83).
Conclusion(s): Our data support the hypothesis that high concentrations of vitamin D decrease ﬁbroid development but are limited by
the few participants with serum 25(OH)D R30ng/mL. Interventional trials that raise and maintain 25(OH)D concentrations >30ng/mL
and then prospectively monitor ﬁbroid development are needed to further assess supplemental vitamin D efﬁcacy and determine
optimal treatment protocols. (Fertil SterilÒ 2022;-:-–-. Ó2022 by American Society for Reproductive Medicine.)
DIALOG: You can discuss this article with its authors and other readers at https://www.fertstertdialog.com/posts/35341
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terine ﬁbroids are noncancerous
tumors of the myometrium that
cause signiﬁcant morbidity
including menorrhagia and pelvic pain,
often requiring medical or surgical intervention (1). Estimates based on ﬁndings
of ultrasound screening suggest that ﬁbroids develop in >70% of women.
Black women have a 10-year earlier tumor onset compared with White women
(2); they also have larger tumors, more
debilitating symptoms, and an increased
need for surgery (3). Existing medical
and surgical treatments for ﬁbroids can
impact childbearing goals, and apart

U
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from hysterectomy, most treatments do not preclude ﬁbroid
recurrence (1). Most individuals with ﬁbroids prefer noninvasive treatments and preservation of the uterus (4).
Despite the high prevalence of ﬁbroids, few modiﬁable
risk factors have been identiﬁed. However, none explains
the differences in disease severity between Black and White
individuals (3, 5). Vitamin D concentration, which is lower
on average among self-identiﬁed Black women, has been proposed as a possible modiﬁable risk factor for the development
of ﬁbroids (6–9). In vitro and animal studies support a
protective effect of vitamin D. In these models, vitamin D
reduces ﬁbroid tissue proliferation, changes the expression
of estrogen and progesterone receptors, alters gene
expression in proliferation and apoptosis pathways, and
reduces expression of extracellular matrix proteins (8, 10–
18). Human observational studies report lower fibroid
prevalence among women with higher serum levels of
vitamin D (6, 11). Most (19–22), but not all (23), human
interventional studies document reduced ﬁbroid growth
when participants are treated with vitamin D, but studies
were small (30–205 participants).
Although highly suggestive, the existing laboratory and
epidemiologic literature has limitations. Animal and in vitro
studies usually study the active form of vitamin D (1,25dihydroxyvitamin D [1,25(OH)2D]). These models may not
reﬂect tissue concentrations in humans who obtain vitamin
D through ultraviolet-B (UV-B) light exposure (D3), diet (D2
or D3), or vitamin supplements (D2 or D3) with conversion
to 25-hydroxyvitamin D (25(OH)D) in the liver and ﬁnal conversion to 1,25(OH)2D in the kidney or target tissue. In addition, most epidemiologic studies have relied on clinical
diagnosis or ultrasound detection of prevalent ﬁbroids, but
initial ﬁbroid onset occurs many years before clinical detection (6, 11).
We hypothesize that higher concentrations of serum
25(OH)D will be associated with reduced ﬁbroid growth and
incidence. We investigated this hypothesis with 4 repeated
standardized ultrasound examinations over 5 years.

METHODS
Study Design
The Study of Environment, Lifestyle and Fibroids (SELF) is a
prospective cohort study designed to evaluate both ﬁbroid
growth and incidence (24). Because of earlier ﬁbroid onset
in Black and African American women in the United States,
SELF enrollment was limited to those who self-identiﬁed as
‘Black or African American’ among a list of racial and ethnic
groups (2). Details of study recruitment and activities are provided in Appendix 1. Brieﬂy, recruitment was conducted in
the Detroit, Michigan area from 2010 to 2012 in collaboration
with Henry Ford Health. Eligible participants were aged 23–
34 years, who reported no previous diagnosis of ﬁbroids at
recruitment. The participants completed baseline questionnaires and attended a clinic visit that included an ultrasound
examination, anthropometric measurements, and nonfasting
blood collection. Of 1,693 participants enrolled, 1,610 (95%)
attended R1 of the 3 follow-up visits during which the
same study activities were completed. The 4 study visits
2

occurred approximately 20 months apart and were completed
in 2018. Participants who missed a visit were encouraged to
attend the next. Visits for pregnant participants were delayed
until 3–4 months postpartum for better ultrasound imaging.
Study retention was high; 91% of the enrolled cohort attended
the ﬁnal visit, 95% attended R2 visits, and 79% attended all 4
study visits (Supplemental Fig. 1, available online). The 5%
who only attended the enrollment visit tended to be older
with lower income, lower body mass index (BMI) and were
more likely to have had a pregnancy. Those participants
who attended all 4 visits tended to be older and were more
likely to be employed compared with those who attended
only 2 or 3 visits, but otherwise the data showed no clear
pattern of differences in baseline characteristics
(Supplemental Table 1, available online).
The Study of Environment, Lifestyle and Fibroids was
approved by the institutional review boards of the National
Institutes of Health and Henry Ford Health. All participants
provided written informed consent and received
compensation.

Measurement of 25(OH)D Concentration
Serum from each visit was aliquoted and stored at -80  C until
assayed. Analysis of 25(OH)D was conducted in 3 batches
(serum from baseline, follow-up 1, and follow-up 2). Details
of the vitamin D measurement and quality control procedures
are described in Appendix 2. In brief, total serum 25(OH)D for
the baseline visit was measured using LIAISON, a competitive
chemiluminescence immunoassay (25, 26). For subsequent
visits serum 25-hydroxyvitamin D2 (25(OH)D2) and 25hydroxyvitamin D3 (25(OH)D3) were measured with liquid
chromatography-tandem mass spectrometry and summed to
create a total 25(OH)D measure. Blinded quality control serum
samples were included in all assays, and based on these samples all intra-assay coefﬁcients of variation were <5%,
whereas inter-assay coefﬁcients of variation were 9% for
LIAISON and <5% for liquid chromatography-tandem mass
spectrometry. The total 25(OH)D concentrations for 77 samples run on both platforms showed a mean difference of 0.6
ng/mL (25th–75th percentiles, 1.8 to 1.1). We did not adjust
for different assay methods.
To account for seasonal variation in 25(OH)D, we estimated the overall annual average 25(OH)D using a cosinor
model (27). We modeled the natural log of 25(OH)D using
the sine and cosine of the day of the year of blood sample
collection (ﬁrst and second harmonic) as predictors (27, 28).
We then created individual values for annual average
25(OH)D by adding the residual for each participant's visit
to the model intercept and transforming back to the original
scale (ng/mL). This season-adjusted 25(OH)D is denoted
25(OH)D hereafter.
For 90 samples, the serum volume was insufﬁcient for the
25(OH)D assay (1.2%–2.6% of samples at a given visit). We
imputed the majority (N ¼ 80) of these values using the
mean of measured values from adjacent visits, or carryover
of the value from an adjacent visit if there was only 1. The remaining observations (N ¼ 10) were dropped from the
analyses.
VOL. - NO. - / - 2022
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We used clinically relevant cut points based on recommendations from the Institute of Medicine (IOM) (29) and
the Endocrine Society (ES) (30) to categorize individual
season-adjusted 25(OH)D values for analyses: <12 ng/mL
(vitamin D deﬁcient) (IOM and ES), <20 ng/mL (vitamin D inadequacy [IOM] or deﬁcient [ES]), <30 ng/mL (vitamin D
insufﬁcient [ES]).

Uterine Fibroid Assessment
Experienced sonographers, trained on the SELF protocol, used
transvaginal ultrasound to count, localize, and measure ﬁbroids R0.5 cm in diameter. Sonographers made 3 separate
passes through the uterus, recording the 3 diameters of a
given tumor at each pass. We calculated the ﬁbroid volume
for each pass with the ellipsoid formula, and the 3 volumes
were averaged for analysis. Per protocol, sonographers noted
any problems with visualization (e.g., calciﬁcations, shadowing) that may have limited visualization. Video and still images were archived, and an 8% sample for each
sonographer, oversampled for ﬁbroid cases, was reviewed
every month by the lead sonographer (details in Appendix 3).
The primary outcomes of interest were ﬁbroid growth and
ﬁbroid incidence. Given the observed reduction in ﬁbroid
growth, ﬁbroid loss was explored as a secondary outcome.
Every ﬁbroid outcome analysis had different eligibility
criteria given that ﬁbroid growth and loss require a ﬁbroid
to be detected and ﬁbroid incidence is estimated among those
who are ﬁbroid-free at enrollment (Supplemental Fig. 2,
available online).
Fibroid growth. The lead sonographer (TC) and 1 other investigator (DDB) identiﬁed ﬁbroids that could be seen across 2
successive visits using archived images and ﬁbroid locations.
The growth analyses used data from 434 participants (n ¼
1,357 interval growth measurements from successive visits).
We deﬁned ﬁbroid growth as the change in the natural logarithm of the tumor volume (ln-volume). Change in ln-volume
was scaled to a growth rate per 18 months (median time between visits ¼19 months; 25th–75th percentiles: 18–21) by
calculating daily growth rates and multiplying by 540. To
compare growth of ﬁbroids from participants in high vs.
low categories of 25(OH)D we estimated percent difference
in volume per 18 months (Appendix 4).
Fibroid incidence. We identiﬁed incident ﬁbroid cases (ﬁrst
appearance of any ﬁbroids) among participants conﬁrmed
via ultrasound examination not to have ﬁbroids at enrollment
(N ¼ 1,246). If sonographers noted factors which impaired
detection of ﬁbroids (e.g., calciﬁcations or shadowing, only
a transabdominal ultrasound) the data were excluded from
analysis (0.5% of ultrasounds), resulting in incidence data
for 1,232 participants. After excluding observations with
insufﬁcient serum for 25(OH)D, the incidence analysis
included 1,230 participants (Supplemental Fig. 2).
Fibroid loss. Fibroid loss was assessed among participants
with prevalent ﬁbroids at enrollment that had not been clinically diagnosed previously, or participants who developed
incident ﬁbroids. For analysis of ﬁbroid loss, deﬁned as a
decrease in ﬁbroid number between 2 successive visits, we
VOL. - NO. - / - 2022

excluded intervals including, or after, a myomectomy, hysterectomy, or uterine artery embolization. When there are
numerous ﬁbroids, it can be difﬁcult to accurately count tumors; therefore, we restricted this analysis to the 539 participants who had R2 successive visits with %4 ﬁbroids at
the earlier visit and no sonographer report of difﬁculty with
visualization (Supplemental Fig. 2) (31). Fibroids that become
undetectable by ultrasound between visits include those that
shrink below the limit of ultrasound detection (0.5 cm for any
diameter); therefore, this outcome cannot be interpreted as
complete resolution of ﬁbroids.

Covariate Assessment
We identiﬁed covariates of interest based on prior ﬁbroid
research, previous work in this cohort, and availability of
SELF data (5, 32, 33). We measured height during the ﬁrst
clinic visit, and weight at every visit to calculate BMI (kg/
m2) for each visit. We collected other covariate data via
telephone or computer-assisted questionnaires at every
visit including reproductive and hormonal variables (years
since last birth, parity, age at menarche, years since last use
of depot medroxyprogesterone acetate [DMPA]), demographic variables (household income, educational attainment, current employment), physical activity, and current
smoking. All factors of interest were explored in adjusted
models and those that did not affect observed associations
between 25(OH)D and the ﬁbroid outcome were not
included in ﬁnal models (34). Parameterization of covariates (categorization or continuous) for modeling is noted
in the table footnotes for each ﬁbroid outcome. Categorical
covariates were usually modeled using indicator variables
to allow for nonlinear associations. Covariates were updated at the beginning of each interval, except for years
since last birth and parity, which were updated at the end
of the interval between visits to incorporate events during
the interval (35). There were minimal missing covariate
data (<0.5%); therefore, when adjusting, we conducted
complete-case analyses.

Statistical Analyses
Analysis of ﬁbroid growth. We used linear mixed models to
account for correlated growth among ﬁbroids from the
same participant and for the same ﬁbroid over time as previously described (32, 33, 36). Minimally adjusted growth
models included time-varying 25(OH)D, continuous age,
and categorical values for ﬁbroid volume and number. Fully
adjusted models included the minimal adjustment set plus
age at menarche and time-varying measures of income,
employment, BMI, years since last birth, and years since last
DMPA use (Appendix 4).
Analysis of ﬁbroid incidence. We used Cox regression with
age as the time scale to estimate hazard ratios and 95% conﬁdence intervals (95% CIs) for associations between 25(OH)D
categories and ﬁbroid incidence. Participants were included
from the age at enrollment until the age at ﬁbroid detection,
with censoring for loss to follow-up, nonﬁbroid-related hysterectomy, or the ﬁnal study visit, whichever occurred ﬁrst.
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Age-adjusted models examining the association between
25(OH)D and ﬁbroid incidence were estimated ﬁrst without
covariates, and then were further adjusted for BMI, current
smoking, income, parity, years since last birth, and years
since last DMPA use. There was no evidence that the proportional hazards assumption was violated.

Analysis of ﬁbroid loss. We used Poisson regression accounting for multiple observations per participant to estimate risk
ratios and 95% CI with robust standard errors for ﬁbroid
loss. Minimally adjusted models included time-varying
25(OH)D, continuous age, months between visits, and categorical values for largest ﬁbroid volume and number of

TABLE 1
Participant characteristics at enrollment, Study of Environment Lifestyle & Fibroids, Detroit, MI 2010–2012.

a

Characteristic

Overall (N [ 1,610)

25(OH)D
(<20 ng/mL)
(N [ 1179)b

25(OH)D
(‡20 ng/mL)
(N [ 424)b

15.3 (11.1–20.6)

12.9 (10.2–16.2)

25.2 (22.3–30.1)

29.2  3.4

29.1  3.4

29.5  3.4

c

Baseline 25(OH)D (ng/mL)
Median (IQR)
Age (y)
Mean  SD
Highest educational attainmentd
High school/general education
diploma
Some college/associates/technical
Bachelors/masters/doctorate
Currently employed
Household incomed
<$20,000
$20,000–$50,000
>$50,000
Body mass index (kg/m2)
<25
25–<30
30–<35
35–<40
R40
Current smoker
Age at menarche (y)
<11
11
12
13
R14
Parity
Never pregnant
Prior pregnancy, no births
1–2 births
R3 births
Years since last birth (y)
No birth
<3
3–4
5–9
R10
Current OCP use
Years since last use of DMPAd
Never used DMPA
<2 years
R2 years
Categorical baseline 25(OH)D (ng/mL)a, b, c
<12
12–<20
20–<25
25–<30
R30

353 (22)

288 (24)

65 (15)

807 (50)
449 (28)
1,002 (62)

618 (52)
272 (23)
704 (60)

186 (44)
173 (41)
292 (69)

721 (45)
605 (38)
272 (17)

574 (49)
429 (36)
168 (14)

145 (34)
172 (41)
103 (24)

318 (20)
331 (21)
310 (19)
267 (17)
384 (24)
310 (19)

211 (18)
235 (20)
202 (17)
218 (18)
313 (27)
261 (22)

106 (25)
96 (23)
107 (25)
48 (11)
67 (16)
48 (11)

297 (18)
325 (20)
430 (27)
274 (17)
284 (18)

212 (18)
235 (20)
324 (27)
199 (17)
209 (18)

82 (19)
90 (21)
103 (24)
75 (18)
74 (17)

432 (27)
192 (12)
708 (44)
278 (17)

320 (27)
137 (12)
504 (43)
218 (18)

109 (26)
55 (13)
201 (47)
59 (14)

624 (39)
360 (22)
207 (13)
291 (18)
128 (8)
183 (11)

457 (39)
256 (22)
146 (12)
226 (19)
94 (8)
98 (8)

164 (39)
101 (24)
61 (14)
64 (15)
34 (8)
85 (20)

920 (57)
183 (11)
506 (31)

661 (56)
142 (12)
375 (32)

253 (60)
41 (10)
130 (31)

495 (31)
684 (42)
209 (13)
108 (7)
107 (7)

495 (42)
684 (58)
—
—
—

—
—
209 (49)
108 (25)
107 (25)

Note: 25(OH)D ¼ 25-hydroxyvitamin D; IQR ¼ Interquartile range with 25th and 75th percentile shown; OCP ¼ oral contraceptive pill, combined estrogen and progestin only; DMPA ¼ depot
medroxyprogesterone acetate (Depo-Provera), injection progestin-only contraceptive.
a
N (%) unless otherwise speciﬁed.
b
N ¼ 7 participants are missing a baseline 25(OH)D measure.
c
Season-adjusted 25(OH)D measure.
d
Missing data: Education n ¼ 1 missing (<20ng/mL); Income n ¼ 12 missing (8 <20ng/mL, 4 R20ng/mL). Years since last use of DMPA n ¼ 1 missing (<20 ng/mL).
Harmon. Vitamin D and ﬁbroid development. Fertil Steril 2022.
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ﬁbroids. Fully adjusted models included the minimal adjustment set plus time-varying education, BMI, years since last
birth, and years since last DMPA use.
Sensitivity analyses to evaluate potential biases. For all
outcomes, we removed observations with imputed serum
25(OH)D. Because use of estrogen-containing oral contraceptives is associated with increased serum concentrations of
25(OH)D (28), we explored possible confounding by including
current use (yes, no) as a covariate. For ﬁbroid incidence we
set the incidence of ﬁbroids to the midpoint of the interval
rather than end. For ﬁbroid growth and loss we removed covariates for ﬁbroid number and ﬁbroid volume to evaluate the
possible inﬂuence of exposure-related differences in ﬁbroid
number and size. For ﬁbroid growth we excluded statistical
outliers (positive or negative growth beyond 3SD). (Details
in Appendix 5). All analyses used SAS 9.4 (Cary, NC).

RESULTS
At enrollment, among the 1,610 participants who had R1
follow-up visit, mean age was 29.2  3.4 years, 78% had
educational attainment beyond high school, 62% were employed, and 45% had a household income below $20,000.
Almost a quarter (24%) had a BMI R40 kg/m2 (Table 1). Participants had low 25(OH)D (median 25(OH)D¼15.3 ng/mL,
25th–75th percentiles: 11.1–20.6). Compared to those with
25(OH)D <20ng/mL, those with 25(OH)D R20ng/mL had
higher educational attainment and income, lower BMI, and
were more likely to be using oral contraceptives and be nonsmokers (Table 1). There was no time trend in 25(OH)D concentrations across the study’s duration (2010–2016)
(Supplemental Fig. 3, available online). Median 25(OH)D concentrations were 15.3 ng/mL at enrollment, 14.8 ng/mL at
follow-up 1, and 15.3 ng/mL at follow-up 2. Among 25(OH)
D measures across the study, 32% were deﬁcient (<12 ng/
mL), 41% were 12–<20 ng/mL, 27% were R20 ng/mL.
Only 7% exceeded the ES cut point for sufﬁciency (R30
ng/mL) (Supplemental Fig. 4, available online) (30). Very
few (1.7%) of the participants had concentrations R30 ng/
mL at all 3 visits. Participants had a median length of study
participation of 4.8 years (25th–75th percentiles: 4.7–5.0).
Baseline characteristics were similar for the participants in
each of the ﬁbroid outcome groups (growth, incidence, and
loss analyses), except for age, percent nulliparous, recency
of birth, and use of DMPA. These are known factors associated
with ﬁbroid prevalence and are expected to differ because the
growth and loss analyses require participants with ﬁbroids,
whereas the incidence analysis requires participants without
ﬁbroids (Supplemental Table 2, available online).
Most ﬁbroids, including undiagnosed ﬁbroids detected at
enrollment and incident ﬁbroids that developed during the
study, were small. Median volume of the incident ﬁbroids at
time of ﬁrst detection was 0.56 cm3 (25th–75th percentiles:
0.2–1.4 cm3). Median volume for those followed for growth
was 2.2 cm3 (25th–75th percentiles: 0.7–8.6 cm3). At enrollment, 23% of participants had R1 ﬁbroid (median: 1 ﬁbroid,
75th percentile: 2 ﬁbroids), whereas by the study’s end, 32%
had R1 ﬁbroid (median: 2 ﬁbroids, 75th percentile: 3
ﬁbroids).
VOL. - NO. - / - 2022

Overall estimated ﬁbroid growth averaged 77.0% (95%
CI: 68.6%, 85.9%) volume increase per 18 months. Serum
25(OH)D R20 ng/mL was associated with a reduced ﬁbroid
growth rate. Fibroids among those with 25(OH)D R20 ng/
mL had 9.7% less growth per 18 months (95% CI: -17.3%,
-1.3%) than ﬁbroids from participants with 25(OH)D <20
ng/mL (Table 2).
Fibroid incidence averaged 9.6% within each study interval. Only at 25(OH)D concentrations R30 ng/mL was there
any indication of a decrease in incidence (Table 3). Hazard ratios for serum 25(OH)D R30 ng/mL suggested an estimated
22% reduction in ﬁbroid incidence (hazard ratio¼ 0.78,
95% CI: 0.47, 1.30) when compared with serum 25(OH)D
<30 ng/mL. Associations were imprecise given the small
number of 25(OH)D measures R30 ng/mL.
Fibroid loss during an interval was common (24.3% of
eligible intervals had loss of at least one ﬁbroid between study
visits). Participants with 25(OH)D concentration R30 ng/mL
had 32% higher ﬁbroid loss in an observation interval than
those with 25(OH)D <30 ng/mL (risk ratio¼ 1.32; 95% CI,
0.95, 1.83) (Table 4).
Sensitivity analyses showed very similar associations to
those in the primary analyses (Appendix 4), (Supplemental
Table 3, available online).

DISCUSSION
Using prospectively collected ultrasound data and repeated
measures of serum 25(OH)D, we observed slower ﬁbroid
growth in participants with 25(OH)D R20 ng/mL. For participants with serum 25(OH)D R30 ng/mL, we found evidence
for a greater likelihood of ﬁbroid loss, but only limited evidence for reduced incidence given the wide conﬁdence
intervals.
In this cohort, there were few 25(OH)D observations R20
ng/mL (27%) or R30 ng/mL (7%). Only 1.7% of participants
maintained 25(OH)D concentrations R30 ng/mL for all 3
measures. Thus, we had limited power to detect associations
at higher concentrations of 25(OH)D. The optimal range of
25(OH)D is debated (37). Although the IOM has identiﬁed
R20 ng/mL as needed for skeletal health (29), the ES argues
that concentrations R30 ng/mL are needed (30). Observational and clinical trials for improved reproductive outcomes
including the success of fertility treatment, fecundability in
natural conceptions, preterm birth, menstrual cycle characteristics, and breast cancer risk suggest that concentrations
of 25(OH)D R40 ng/mL may be required (38–42).
Although most ﬁbroids in this cohort were small and
might not warrant immediate clinical attention, our study still
has important clinical implications. Symptoms and major interventional treatments are more likely with larger ﬁbroids
(43,44). Therefore, minimizing ﬁbroid growth and increasing
ﬁbroid loss when ﬁbroids are small can delay severe
morbidity and prevent the need for surgical or radiologic
treatments.
Our ﬁndings for reduced growth of ﬁbroids from participants with higher 25(OH)D levels are consistent with results
of small clinical trials that treated participants with vitamin
D supplements, although most of those studies included
5
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TABLE 2
Serum 25(OH)D and ﬁbroid growth, 434a participants from the Study of Environment, Lifestyle & Fibroids, Detroit, Michigan, 2010–2018
Estimated % difference in growth (95% CI)
Categories of 25(OH)D ng/mL

No. growth intervals

Minimally adjustedb

394
524
321
118

REF
2.8 (7.1, 13.7)
6.6 (16.9, 5.0)
7.7 (21.9, 9.1)

REF
4.7 (5.0, 15.4)
6.3 (16.4, 5.0)
9.1 (22.6, 6.8)

918
439

REF
8.4 (16.4, 0.3)

REF
9.7 (17.3, 1.3)

1,239
118

REF
6.5 (19.6, 8.7)

REF
8.8 (21.0, 5.4)

Four categories of 25(OH)D
<12
12–<20
20–<30
R30
Two categories of 25(OH)D split at 20 ng/mL
<20
R20
Two categories of 25(OH)D split at 30 ng/mL
<30
R30

Fully adjustedc

Note: 25(OH)D ¼ 25-hydroxyvitamin D; CI ¼ conﬁdence interval.
a
Growth analyses were conducted among ﬁbroids which could be matched across successive visits based on ﬁbroid location. This includes ﬁbroids from 434 participants with 1357 interval growth
measurements. Participants could contribute multiple ﬁbroids and ﬁbroids could be followed across multiple intervals.
b
Minimally adjusted model includes volume of ﬁbroid (<0.5 cm3,0.5–4.19 cm3,4.2–14.0 cm3,R14.1 cm3), number of ﬁbroids (ordinal 1, 2, 3, R4), age (continuous).
c
Fully adjusted models further adjust for years since last birth (<5 years, R5 years ago including no birth), years since last use of injection contraceptive (<2 years, R2 years/never), body mass index
(kg/m2) (<25, 25–<30, 30–<35, 35–<40, R40), income (<$20,000, $20–50,000, >$50,000), employment (employed yes/no), age at menarche (ordinal <11, 11, 12, 13, >13 years). Three observations excluded from analyses because of missing data on at least one covariate.
Harmon. Vitamin D and ﬁbroid development. Fertil Steril 2022.

participants with 25(OH)D concentrations ranging up to 30
ng/mL at enrollment, and treated with supplementation that
would have resulted in higher concentrations than generally
seen in our sample (19–22). Fibroid loss was not included as
an outcome in the trials of ﬁbroid growth. However, if our
ﬁnding of reduced ﬁbroid growth with higher vitamin D
results in some ﬁbroids shrinking below the ultrasound
detection limit, increased ﬁbroid loss would be expected.
Although the association between vitamin D and ﬁbroid
incidence has not been previously studied, a recent systematic
review and additional observational studies report lower concentrations of 25(OH)D among women with prevalent ﬁbroids
than those without ﬁbroids (6, 45–47). The observational
studies rely on self-reported ﬁbroid status, and this results

in undiagnosed ﬁbroids being included in the ‘‘noncase’’
group (5) as well as temporal misclassiﬁcation of 25(OH)D
concentrations. A large, randomized control trial using prospective ultrasound examinations is underway in China
which will investigate the effects of daily vitamin D supplementation over 2 years on ﬁbroid incidence in >2000 women,
and ﬁbroid growth in 360 women (48). Trials in other populations are warranted.
In vitro and animal models support our ﬁnding that
vitamin D limits ﬁbroid growth as reviewed recently by Vergara et al. (10). In vitro models including those using immortalized human uterine leiomyoma cells (HuLM) and cultured
human cells from ﬁbroid and adjacent myometrial tissue
show that treatment with 1,25(OH)2D inhibits their growth

TABLE 3
Serum 25(OH)D and ﬁbroid incidence, 1230a participants from the Study of Environment, Lifestyle & Fibroids, Detroit, Michigan, 2010–2018
Categories of 25(OH)D
(ng/mL)

Hazard ratio (95% conﬁdence interval)
Incident cases

Four categories of 25(OH)D
<12
88
12-<20
119
20-<30
71
R30
16
Two categories of 25(OH)D split at 20 ng/mL
<20
207
R20
87
Two categories of 25(OH)D split at 30 ng/mL
<30
278
R30
16

Unadjustedb

Fully adjustedc

1,717
2,213
1,075
303

REF
1.06 (0.81, 1.40)
1.23 (0.90, 1.68)
0.91 (0.53, 1.55)

REF
1.03 (0.78, 1.37)
1.15 (0.83, 1.58)
0.83 (0.48, 1.42)

3,930
1,377

REF
1.11 (0.87, 1.43)

REF
1.05 (0.81, 1.36)

5,004
303

REF
0.84 (0.51, 1.39)

REF
0.78 (0.47, 1.30)

Person-years

Note: 25(OH)D ¼ 25-hydroxyvitamin D
a
Incidence analyses were conducted among 1,230 participants who were ﬁbroid-free at enrollment and had at least one follow-up ultrasound.
b
Cox model with age as time scale (starting at age of enrollment), with no further adjustment.
c
Cox model with age as time scale further adjusted for time-varying parity (0, 1-2 births, R3 births), years since last birth (within 4 years, R4 years ago including no births), years since last use of
injection contraceptive (<2 years, R2 years/never), body mass index (kg/m2) (<25, 25–<30, 30–<35, 35–<40, R40), current smoking (yes, no), household income (<$20,000, R$20,000). Twelve
observations excluded from analyses because of missing data on at least one covariate.
Harmon. Vitamin D and ﬁbroid development. Fertil Steril 2022.

6

VOL. - NO. - / - 2022

Fertility and Sterility®

TABLE 4
Serum 25(OH)D and ﬁbroid loss in 539a participants in the Study of Environment, Lifestyle & Fibroids, Detroit, Michigan, 2010–2018
Categories of 25(OH)D (ng/
mL)

Risk ratio (95% conﬁdence interval)

Intervals with loss/eligible
intervals (%)

Minimally adjustedb

Fully adjustedc

71/319 (22.3)
97/406 (23.9)
56/217 (25.8)
24/77 (31.2)

REF
1.04 (0.80, 1.35)
1.04 (0.76, 1.42)
1.29 (0.88, 1.88)

REF
1.06 (0.81, 1.38)
1.14 (0.83, 1.57)
1.40 (0.95, 2.06)

168/725 (23.2)
80/294 (27.2)

REF
1.08 (0.86, 1.36)

REF
1.17 (0.92, 1.48)

224/942 (23.8)
24/77 (31.2)

REF
1.26 (0.90, 1.75)

REF
1.32 (0.95, 1.83)

Four categories of 25(OH)D
<12
12–<20
20–<30
R30
Two categories of 25(OH)D split at 20 ng/mL
<20
R20
Two categories of 25(OH)D split at 30 ng/ml
<30
R30

Note: 25(OH)D, 25-hydroxyvitamin D; HS/GED, High school/general education diploma.
a
Loss analyses were conducted among 539 participants with 1-4 prevalent ﬁbroids at the beginning of an observed interval. This includes participants with ﬁbroids at enrollment and those who
develop incident ﬁbroids.
b
Minimally adjusted model includes age (continuous), months between visits (continuous), number of ﬁbroids (1, 2, R3) and volume of largest ﬁbroid (<0.5 cm3,0.5–4.19 cm3,4.2–14.0
cm3,R14.1 cm3).
c
Fully adjusted model also includes years since last birth (<4 years, R4 years ago including no birth), years since last use of injection contraceptive (<2 years, R2 years/never), body mass index (kg/
m2) (<25, 25–<30, 30–<35, 35–<40, R40), education (HS/GED or less, >HS/GED). Four observations excluded from analyses because of missing data on at least one covariate.
Harmon. Vitamin D and ﬁbroid development. Fertil Steril 2022.

through changes in cell proliferation, apoptosis, extracellular
matrix composition, Wnt/b-catenin, and TGFb3 expression,
and down-regulation of estrogen and progesterone receptors
(12, 13, 16, 18, 49–51). Treatment with 1,25(OH)2D or an
analogue in mice and Eker rats with ﬁbroid tumors also
results in decreased tumor size through such mechanisms
(17, 50, 52).
Limited laboratory studies were conducted related to
ﬁbroid initiation and vitamin D. Most ﬁbroids harbor speciﬁc
somatic mutations in HMGA2 or MED12 (53). Fibroids have
elevated DNA damage and vitamin D treatment of HuLM cells
reduced the evidence of DNA damage with up-regulation of
DNA-repair proteins (14). Improved detection and repair of
DNA damage could prevent the proliferation of cells with mutations and thus limit ﬁbroid initiation (54).
An inherent limitation to studying the growth of individual ﬁbroids is that they must be observed over time, and lost
ﬁbroids are not included; to compensate, we examined ﬁbroid
loss as a separate outcome. There is also measurement error in
ultrasound assessment of ﬁbroid size, and very small ﬁbroids
may be missed. However, taking 3 separate passes through the
uterus will maximize ﬁbroid detection, and using the mean of
3 separate volume measures has less measurement error than
a single measure. In addition, measurement error is greater for
smaller ﬁbroids (55), but we address this limitation by accounting for the differential error in our growth model (33).
The most important limitation is that we had few participants
with 25(OH)D concentrations >30 ng/mL which limits our power to ﬁnd associations at the higher vitamin D concentrations recommended by the ES.
Our prospective study design with multiple standardized
ultrasounds is the ﬁrst that allows for the timely detection
of incident ﬁbroids, thus reducing the misclassiﬁcation of
ﬁbroid status which is present in previous observational
studies. Our multiple measures of serum 25(OH)D reduce the
bias introduced when a single measure of 25(OH)D is assumed
to be relevant for later timepoints. In addition, our focus on
VOL. - NO. - / - 2022

Black women allows us to examine individuals at high risk
for both vitamin D deﬁciency and ﬁbroid burden, although
vitamin D deﬁciency among reproductive-aged women in
the United States is widespread (7).
Vitamin D is well known to be critical for bone health (29)
with growing evidence that higher concentrations of 25(OH)D
improve reproductive outcomes (56) and reduce breast cancer
risk (42). Our ﬁndings add support to the existing literature
suggesting vitamin D may also reduce ﬁbroid development.
As compared with existing medical and surgical treatments
for ﬁbroids that have signiﬁcant side-effects and impact
fertility, vitamin D is safe and compatible with pregnancy.
The high prevalence of vitamin D deﬁciency in the SELF
cohort and reproductive-aged US women in general (47) suggests that further public health awareness about vitamin D is
needed. An additional issue for US women is that elevated
BMI is associated with lower 25(OH)D concentrations (57).
Current dietary and supplement recommendations for
vitamin D intake may not be sufﬁcient for individuals with
high BMI who require 2–3 times higher vitamin D supplementation to attain desired serum concentrations (58).
In conclusion, 25(OH)D concentrations >20 ng/mL were
associated with reduced ﬁbroid growth. Results for analyses
examining 25(OH)D concentrations >30 ng/mL provided
suggestive evidence for increased likelihood of ﬁbroid loss
and a possible reduction in ﬁbroid incidence. Intervention trials with vitamin D supplementation to attain and maintain
sufﬁcient 25(OH)D will be needed to further assess the impact
of vitamin D on ﬁbroid development.
Acknowledgments: The authors thank Drs. Anne Marie
Jukic, Ph.D., Katie O’Brien, Ph.D., and Christine Langton,
Ph.D. for helpful comments on a previous draft of this manuscript.
DIALOG: You can discuss this article with its authors and
other readers at https://www.fertstertdialog.com/posts/
35341
7

ORIGINAL ARTICLE: ENVIRONMENT AND EPIDEMIOLOGY

REFERENCES
1.
2.

3.
4.

5.
6.
7.

8.
9.

10.
11.

12.

13.

14.

15.

16.

17.

18.

19.

20.

21.

22.

23.

8

Management of symptomatic uterine leiomyomas: ACOG practice bulletin,
number 228. Obstet Gynecol 2021;137:e100–15.
Laughlin SK, Baird DD, Savitz DA, Herring AH, Hartmann KE. Prevalence of
uterine leiomyomas in the ﬁrst trimester of pregnancy: an ultrasoundscreening study. Obstet Gynecol 2009;113:630–5.
Laughlin-Tommaso SK, Jacoby VL, Myers ER. Disparities in ﬁbroid incidence,
prognosis, and management. Obstet Gynecol Clin North Am 2017;44:81–94.
Borah BJ, Nicholson WK, Bradley L, Stewart EA. The impact of uterine leiomyomas: a national survey of affected women. Am J Obstet Gynecol 2013;
209:319, e1–.e20.
Wise LA, Laughlin-Tommaso SK. Epidemiology of uterine ﬁbroids: from
menarche to menopause. Clin Obstet Gynecol 2016;59:2–24.
Baird DD, Hill MC, Schectman JM, Hollis BW. Vitamin D and the risk of uterine ﬁbroids. Epidemiology 2013;24:447–53.
Herrick KA, Storandt RJ, Afful J, Pfeiffer CM, Schleicher RL, Gahche JJ, et al.
Vitamin D status in the United States, 2011–2014. Am J Clin Nutr 2019;110:
150–7.
Brakta S, Diamond JS, Al-Hendy A, Diamond MP, Halder SK. Role of vitamin
D in uterine ﬁbroid biology. Fertil Steril 2015;104:698–706.
Wise LA, Ruiz-Narv
aez EA, Haddad SA, Rosenberg L, Palmer JR. Polymorphisms in vitamin D-related genes and risk of uterine leiomyomata. Fertil
Steril 2014;102:503–10.e1.
Vergara D, Catherino WH, Trojano G, Tinelli A. Vitamin D: mechanism of action and biological effects in uterine ﬁbroids. Nutrients 2021;13.
Mohammadi R, Tabrizi R, Hessami K, Ashari H, Nowrouzi-Sohrabi P, Hosseini-Bensenjan M, et al. Correlation of low serum vitamin-D with uterine
leiomyoma: a systematic review and meta-analysis. Reprod Biol Endocrinol
2020;18:85.
Al-Hendy A, Diamond MP, El-Sohemy A, Halder SK. 1,25-dihydroxyvitamin
D3 regulates expression of sex steroid receptors in human uterine ﬁbroid
cells. J Clin Endocrinol Metab 2015;100:E572–82.
Sharan C, Halder SK, Thota C, Jaleel T, Nair S, Al-Hendy A. Vitamin D inhibits
proliferation of human uterine leiomyoma cells via catechol-o-methyltransferase. Fertil Steril 2011;95:247–53.
Ali M, Shahin SM, Sabri NA, Al-Hendy A, Yang Q. Hypovitaminosis D exacerbates the DNA damage load in human uterine ﬁbroids, which is ameliorated by vitamin D3 treatment. Acta Pharmacol Sin 2019;40:957–70.
Al-Hendy A, Diamond MP, Boyer TG, Halder SK. Vitamin D3 inhibits Wnt/bcatenin and mTOR signaling pathways in human uterine ﬁbroid cells. J Clin
Endocrinol Metab 2016;101:1542–51.
Halder SK, Osteen KG, Al-Hendy A. 1,25-dihydroxyvitamin D3 reduces
extracellular matrix-associated protein expression in human uterine ﬁbroid
cells. Biol Reprod 2013;89:150.
Halder SK, Sharan C, Al-Hendy A. 1,25-dihydroxyvitamin D3 treatment
shrinks uterine leiomyoma tumors in the Eker rat model. Biol Reprod
2012;86:116.
n J, Escrig J, Faus A,
Corach
an A, Trejo MG, Carbajo-García MC, Monleo
et al. Vitamin D as an effective treatment in human uterine leiomyomas independent of mediator complex subunit 12 mutation. Fertil Steril 2021;115:
512–21.
Arjeh S, Darsareh F, Asl ZA, Azizi Kutenaei M. Effect of oral consumption of
vitamin D on uterine ﬁbroids: a randomized clinical trial. Complement Ther
Clin Pract 2020;39:101159.
Hajhashemi M, Ansari M, Haghollahi F, Eslami B. The effect of vitamin D supplementation on the size of uterine leiomyoma in women with vitamin D
deﬁciency. Caspian J Intern Med 2019;10:125–31.
Ciavattini A, Delli Carpini G, Serri M, Vignini A, Sabbatinelli J, Tozzi A, et al.
Hypovitaminosis D and ‘‘small burden’’ uterine ﬁbroids: opportunity for a
vitamin D supplementation. Med (Baltimore) 2016;95:e5698.
Davari Tanha F, Feizabad E, Vasheghani Farahani M, Amuzegar H, Moradi B,
Samimi Sadeh S. The effect of vitamin D deﬁciency on overgrowth of uterine
ﬁbroids: a blinded randomized clinical trial. Int J Fertil Steril 2021;15:95–100.
Suneja A, Faridi F, Bhatt S, Guleria K, Mehndiratta M, Sharma R. Effect of
vitamin D3 supplementation on symptomatic uterine leiomyoma in women
with hypovitaminosis D. J Mid Life Health 2021;12:53–60.

24.

25.

26.

27.

28.

29.
30.

31.

32.

33.

34.
35.

36.
37.

38.

39.

40.

41.

42.

43.

44.

Baird DD, Harmon QE, Upson K, Moore KR, Barker-Cummings C, Baker S,
et al. A prospective, ultrasound-based study to evaluate risk factors for uterine ﬁbroid incidence and growth: methods and results of recruitment. J
Womens Health (Larchmt) 2015;24:907–15.
Wagner D, Hanwell HE, Vieth R. An evaluation of automated methods for
measurement of serum 25-hydroxyvitamin D. Clin Biochem 2009;42:
1549–56.
Ersfeld DL, Rao DS, Body JJ, Sackrison JL Jr, Miller AB, Parikh N, et al. Analytical and clinical validation of the 25 OH vitamin D assay for the liaison automated analyzer. Clin Biochem 2004;37:867–74.
Sachs MC, Shoben A, Levin GP, Robinson-Cohen C, Hoofnagle AN, SwordsJenny N, et al. Estimating mean annual 25-hydroxyvitamin D concentrations
from single measurements: the multi-ethnic study of atherosclerosis. Am J
Clin Nutr 2013;97:1243–51.
Harmon QE, Umbach DM, Baird DD. Use of estrogen-containing contraception is associated with increased concentrations of 25-hydroxy vitamin D. J
Clin Endocrinol Metab 2016;101:3370–7.
Institute of Medicine Food and Drug Board. Dietary reference intakes for calcium and vitamin D. Washington, DC: National Academy Press; 2010.
Holick MF, Binkley NC, Bischoff-Ferrari HA, Gordon CM, Hanley DA,
Heaney RP, et al. Evaluation, treatment, and prevention of vitamin D deﬁciency: an endocrine society clinical practice guideline. J Clin Endocrinol
Metab 2011;96:1911–30.
Dueholm M, Lundorf E, Hansen ES, Ledertoug S, Olesen F. Accuracy of magnetic resonance imaging and transvaginal ultrasonography in the diagnosis,
mapping, and measurement of uterine myomas. Am J Obstet Gynecol 2002;
186:409–15.
Baird DD, Patchel SA, Saldana TM, Umbach DM, Cooper T, Wegienka G,
et al. Uterine ﬁbroid incidence and growth in an ultrasound-based, prospective study of young African Americans. Am J Obstet Gynecol 2020;223:402,
e1–e18.
Harmon QE, Patchel SA, Zhao S, Umbach DM, Cooper TE, Baird DD. Depot
medroxyprogesterone acetate use and the development and progression of
uterine leiomyoma. Obstet Gynecol 2022;139:797–807.
Mickey RM, Greenland S. The impact of confounder selection criteria on effect estimation. Am J Epidemiol 1989;129:125–37.
Peddada SD, Laughlin SK, Miner K, Guyon JP, Haneke K, Vahdat HL, et al.
Growth of uterine leiomyomata among premenopausal Black and White
women. Proc Natl Acad Sci U S A 2008;105:19887–92.
Laughlin SK, Hartmann KE, Baird DD. Postpartum factors and natural ﬁbroid
regression. Am J Obstet Gynecol 2011;204:496, e1–e6.
Giustina A, Adler RA, Binkley N, Bollerslev J, Bouillon R, Dawson-Hughes B,
et al. Consensus statement from 2(nd) international conference on controversies in vitamin D. Rev Endocr Metab Disord 2020;21:89–116.
Pal L, Zhang H, Williams J, Santoro NF, Diamond MP, Schlaff WD,
et al. Vitamin D status relates to reproductive outcome in women
with polycystic ovary syndrome: secondary analysis of a multicenter
randomized controlled trial. J Clin Endocrinol Metab 2016;101:
3027–35.
Jukic AMZ, Baird DD, Weinberg CR, Wilcox AJ, McConnaughey DR,
Steiner AZ. Pre-conception 25-hydroxyvitamin D (25(OH)D) and fecundability. Hum Reprod 2019;34:2163–72.
McDonnell SL, Baggerly KA, Baggerly CA, Aliano JL, French CB, Baggerly LL,
et al. Maternal 25(OH)D concentrations R40 ng/mL associated with 60%
lower preterm birth risk among general obstetrical patients at an urban
medical center. PLoS One 2017;12:e0180483.
Jukic AMZ, Wilcox AJ, McConnaughey DR, Weinberg CR, Steiner AZ. 25hydroxyvitamin D and long menstrual cycles in a prospective cohort study.
Epidemiology 2018;29:388–96.
O'Brien KM, Sandler DP, Taylor JA, Weinberg CR. Serum vitamin D and risk
of breast cancer within ﬁve years. Environ Health Perspect 2017;125:
077004.
Wegienka G, Baird DD, Hertz-Picciotto I, Harlow SD, Steege JF, Hill MC, et al.
Self-reported heavy bleeding associated with uterine leiomyomata. Obstet
Gynecol 2003;101:431–7.
Baird DD, Saldana TM, Shore DL, Hill MC, Schectman JM. A single baseline
ultrasound assessment of ﬁbroid presence and size is strongly predictive of

VOL. - NO. - / - 2022

Fertility and Sterility®

45.

46.

47.
48.

49.
50.

51.

future uterine procedure: 8-year follow-up of randomLy sampled premenopausal women aged 35-49 years. Hum Reprod 2015;30:2936–44.
Tunau KA, Garba JA, Panti AA, Shehu CE, Adamu AN, AbdulRahman MB,
et al. Low plasma vitamin D as a predictor of uterine ﬁbroids in a Nigerian
population. Niger Postgrad Med J 2021;28:181–6.
Xu F, Li F, Li L, Lin D, Hu H, Shi Q. Vitamin D as a risk factor for the presence of
asymptomatic uterine ﬁbroids in premenopausal Han chinese women. Fertil
Steril 2021;115:1288–93.
Mitro SD, Zota AR. Vitamin D and uterine leiomyoma among a sample of US
women: ﬁndings from nhanes, 2001–2006. Reprod Toxicol 2015;57:81–6.
Sheng B, Song Y, Liu Y, Jiang C, Zhu X. Association between vitamin D and
uterine ﬁbroids: a study protocol of an open-label, randomised controlled
trial. BMJ Open 2020;10:e038709.
Bl€
auer M, Rovio PH, Ylikomi T, Heinonen PK. Vitamin D inhibits myometrial
and leiomyoma cell proliferation in vitro. Fertil Steril 2009;91:1919–25.
Halder SK, Sharan C, Al-Hendy O, Al-Hendy A. Paricalcitol, a vitamin D receptor activator, inhibits tumor formation in a murine model of uterine ﬁbroids. Reprod Sci 2014;21:1108–19.
Corach
an A, Ferrero H, Aguilar A, Garcia N, Monleon J, Faus A, et al. Inhibition of tumor cell proliferation in human uterine leiomyomas by vitamin D via
Wnt/b-catenin pathway. Fertil Steril 2019;111:397–407.

VOL. - NO. - / - 2022

52.

53.

54.

55.

56.

57.
58.

 I, et al. LongCorachan A, Ferrero H, Escrig J, Monleon J, Faus A, Cervello
term vitamin D treatment decreases human uterine leiomyoma size in a
xenograft animal model. Fertil Steril 2020;113:205–16.e4.
Mehine M, M€akinen N, Heinonen HR, Aaltonen LA, Vahteristo P. Genomics
of uterine leiomyomas: insights from high-throughput sequencing. Fertil
Steril 2014;102:621–9.
Elkafas H, Ali M, Elmorsy E, Kamel R, Thompson WE, Badary O, et al. Vitamin
D3 ameliorates DNA damage caused by developmental exposure to endocrine disruptors in the uterine myometrial stem cells of Eker rats. Cells
2020;9.
Moshesh M, Peddada SD, Cooper T, Baird D. Intraobserver variability in
ﬁbroid size measurements: estimated effects on assessing ﬁbroid growth.
J Ultrasound Med 2014;33:1217–24.
Pilz S, Zittermann A, Obeid R, Hahn A, Pludowski P, Trummer C, et al. The
role of vitamin D in fertility and during pregnancy and lactation: a review
of clinical data. Int J Environ Res Public Health 2018;15.
Wortsman J, Matsuoka LY, Chen TC, Lu Z, Holick MF. Decreased bioavailability of vitamin D in obesity. Am J Clin Nutr 2000;72:690–3.
Kimball SM, Holick MF. Ofﬁcial recommendations for vitamin D
through the life stages in developed countries. Eur J Clin Nutr
2020;74:1514–8.

9

